LASER VERSUS CRYSTALLIZED PHENOL IN PILONIDAL SINUS DISEASE
PSD-L-F
A PROSPECTIVE RANDOMIZED COMPARISON OF LASER ABLATION AND CRYSTALLIZED PHENOL APPLICATION IN PRIMARY UNCOMPLICATED SACROCOCCYGEAL PILONIDAL SINUS DISEASE
1 other identifier
interventional
120
0 countries
N/A
Brief Summary
This single-center prospective randomized parallel-group trial compares laser ablation and crystallized phenol application in adults with primary uncomplicated sacrococcygeal pilonidal sinus disease. The primary objective is to compare postoperative day 1 pain intensity between the two treatment methods. Secondary objectives include complete epithelialization by day 30, time to complete epithelialization, postoperative day 7 pain, duration of analgesic use, time to return to daily activities and work, early local complications, and 6-month recurrence.
Trial Health
Trial Health Score
Automated assessment based on enrollment pace, timeline, and geographic reach
participants targeted
Target at P50-P75 for not_applicable
Started Jul 2026
Shorter than P25 for not_applicable
Health score is calculated from publicly available data and should be used for screening purposes only.
Trial Relationships
Click on a node to explore related trials.
Study Timeline
Key milestones and dates
First Submitted
Initial submission to the registry
July 8, 2026
CompletedFirst Posted
Study publicly available on registry
July 14, 2026
CompletedStudy Start
First participant enrolled
July 15, 2026
CompletedPrimary Completion
Last participant's last visit for primary outcome
March 1, 2027
ExpectedStudy Completion
Last participant's last visit for all outcomes
March 1, 2027
July 14, 2026
July 1, 2026
8 months
July 8, 2026
July 8, 2026
Conditions
Keywords
Outcome Measures
Primary Outcomes (1)
Postoperative day 1 pain score
Pain intensity on postoperative day 1 assessed using a 0 to 10 Visual Analog Scale, where 0 indicates no pain and 10 indicates the worst imaginable pain; higher scores indicate worse pain.
Postoperative day 1
Secondary Outcomes (8)
Complete epithelialization at day 30
Postoperative day 30
Time to complete epithelialization
Up to 30 days
Postoperative day 7 pain score
Postoperative day 7
Duration of analgesic use
Up to 30 days
Time to return to daily activities
Up to 30 days
- +3 more secondary outcomes
Study Arms (2)
Laser ablation
EXPERIMENTALParticipants undergo shared sinus preparation followed by laser ablation using a Leonardo Mini 1470 nm diode laser.
Crystallized phenol
ACTIVE COMPARATORParticipants undergo shared sinus preparation followed by crystallized phenol application to the sinus cavity.
Interventions
After a small incision, hair and debris removal, and curettage, laser ablation is performed using a Leonardo Mini 1470 nm diode laser.
After a small incision, hair and debris removal, and curettage, crystallized phenol is applied to the sinus cavity.
Eligibility Criteria
You may qualify if:
- Age 18 years or older
- Diagnosis of primary chronic sacrococcygeal pilonidal sinus disease
- Uncomplicated disease
- Suitability for minimally invasive treatment
- Provision of written informed consent
You may not qualify if:
- Acute pilonidal abscess
- History of pilonidal abscess drainage
- Previous surgical or interventional treatment for pilonidal sinus disease
- Recurrent pilonidal disease
- Complex pilonidal disease or marked lateral extension
- Immunosuppression, chronic steroid use, or systemic conditions that may significantly impair wound healing
- Inability to attend regular follow-up
- Refusal to participate in the study
Contact the study team to confirm eligibility.
Sponsors & Collaborators
MeSH Terms
Conditions
Interventions
Condition Hierarchy (Ancestors)
Intervention Hierarchy (Ancestors)
Central Study Contacts
Study Design
- Study Type
- interventional
- Phase
- not applicable
- Allocation
- RANDOMIZED
- Masking
- NONE
- Purpose
- TREATMENT
- Intervention Model
- PARALLEL
- Sponsor Type
- OTHER GOV
- Responsible Party
- PRINCIPAL INVESTIGATOR
- PI Title
- Principal Investigator
Study Record Dates
First Submitted
July 8, 2026
First Posted
July 14, 2026
Study Start
July 15, 2026
Primary Completion (Estimated)
March 1, 2027
Study Completion (Estimated)
March 1, 2027
Last Updated
July 14, 2026
Record last verified: 2026-07
Data Sharing
- IPD Sharing
- Will not share
Individual participant data will not be shared because this is a single-center clinical study involving sensitive patient-level data, and there is no pre-specified institutional mechanism for external data sharing. Only aggregated, de-identified study results will be reported.